Respiratorius Investor Relations Material
Latest events
Q1 2025
21 May, 2025
Q4 2024
11 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Respiratorius
Access all reports
Respiratorius AB is a Swedish biotechnology company focused on developing drug candidates for the treatment of various diseases, primarily cancer, COPD (Chronic Obstructive Pulmonary Disease), and asthma. Its lead project, VAL001, is aimed at enhancing the treatment of Diffuse Large B-Cell Lymphoma (DLBCL), the most common type of aggressive lymphoma. Additionally, the company is developing substances like the RESP series, which have bronchodilating effects for respiratory conditions such as COPD and asthma. Respiratorius is also working on a cardiovascular biomarker to aid in PET imaging diagnostics. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
RESP
Country
🇸🇪 Sweden